Cash-to-Service: The Inventory Trade-off CFOs Care About

Somewhere in your company right now, a supply chain report is being prepared that will waste a meeting. It will show days of inventory, fill rate, and forecast accuracy. Planners will nod along to it. Finance will ask what it means in cash. And the answer will be a shrug.

I have sat in that meeting, on both sides of the table. The problem is not the numbers. The problem is the language.

Planners and CFOs price risk differently

Planners describe inventory in coverage weeks and service levels, because that is what the planning system optimizes. A CFO prices the same inventory in working capital, write-off risk, and the cost of the capital tied up in it. Neither view is wrong. They are just incompatible at the level where decisions get made.

High stock binds cash and raises obsolescence exposure. Low stock raises the risk of a stock-out, lost revenue, and in pharma, patients who switch products and never switch back. Every inventory position is a position on that trade-off, whether or not anyone states it out loud.

Most companies never state it out loud. The trade-off stays implicit, so every product-market combination gets steered by habit and gut feel instead of by a conscious decision.

The fix is transparency about the trade-off, per product and market

The answer is not "more inventory" and it is not "less inventory". Anyone selling you one of those as a universal answer is selling a slogan. The answer is making the trade-off explicit per product and market, so that someone with budget authority chooses a position instead of inheriting one.

In practice that means every meaningful planning decision gets framed with three numbers on the table: the working capital the position binds, the service level it buys, and the revenue at risk if the position is wrong. When those three numbers are visible, the conversation changes character. It stops being supply chain versus finance and becomes a board-level choice about where the company wants to sit on a known curve.

What this looks like in an executive review

A drug going into a growth market with a two-month safety stock: show the cash that safety stock binds next to the revenue it protects. A mature product with erratic CMO supply: show the write-off exposure of buffering the volatility against the cost of not buffering it. Once the trade-off is visible, most executive teams make braver and faster decisions than planners expect, because for the first time the decision is actually theirs to make.

This reframing is the backbone of how I run S&OP/IBP decision improvement engagements: every scenario and every recommendation is translated into the currency of the people who approve it.